statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...

Pharvaris (PHVS, $21.64) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that PHVS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Pharvaris (PHVS, $23.11) Aroon Indicator entered a Downtrend on March 28, 2024.

Pharvaris (PHVS, $23.5) Aroon Indicator entered a Downtrend on March 27, 2024.

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE attacks...

38,893 Shares in Pharvaris (NASDAQ:PHVS) Purchased by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP purchased a new position in Pharvaris (NASDAQ:PHVS  Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities...

Pharvaris (PHVS, $23.45) Aroon Indicator entered a Downtrend on March 12, 2024.

Pharvaris (PHVS, $23.14) Aroon Indicator entered a Downtrend on March 11, 2024.

Pharvaris (PHVS, $26.47) Aroon Indicator entered a Downtrend on March 08, 2024.

Pharvaris (PHVS, $26.37) Aroon Indicator entered a Downtrend on March 07, 2024.

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

Pharvaris NV

Volume	35,619.00
52-Wk High	$33.00
52-Wk Low	$15.00

PHVS Pharvaris NV

About

Feed

News

Sentiment

Earnings

Fundamentals